12:00 AM
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Deals

Alligator Bioscience, BioInvent deal

BioInvent sold back all rights to preclinical cancer compound ADC-1013 to former partner Alligator for an undisclosed sum. BioInvent has successfully manufactured the antibody-based CD40 receptor activator immunotherapy...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >